ARANESP darbepoetin alfa (rch) 100 microgram/0.5mL injection syringe with automatic needle guard Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 100 microgram/0.5ml injection syringe with automatic needle guard

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

ARANESP darbepoetin alfa (rch) 100 microgram/0.5mL injection syringe within a pen injector Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 100 microgram/0.5ml injection syringe within a pen injector

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: sodium chloride; polysorbate 80; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

ARANESP darbepoetin alfa (rch) 50 microgram/0.5mL injection syringe with automatic needle guard Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 50 microgram/0.5ml injection syringe with automatic needle guard

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium chloride; water for injections; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

ARANESP darbepoetin alfa (rch) 40 microgram/0.4mL injection syringe with automatic needle guard Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 40 microgram/0.4ml injection syringe with automatic needle guard

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; dibasic sodium phosphate; polysorbate 80; monobasic sodium phosphate monohydrate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

ARANESP darbepoetin alfa (rch) 30 microgram/0.3mL injection syringe with automatic needle guard Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 30 microgram/0.3ml injection syringe with automatic needle guard

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: water for injections; monobasic sodium phosphate monohydrate; sodium chloride; dibasic sodium phosphate; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

ARANESP darbepoetin alfa (rch) 40 microgram/0.4mL injection syringe within a pen injector Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 40 microgram/0.4ml injection syringe within a pen injector

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; dibasic sodium phosphate; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

ARANESP darbepoetin alfa (rch) 50 microgram/0.5mL injection syringe within a pen injector Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 50 microgram/0.5ml injection syringe within a pen injector

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: polysorbate 80; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; water for injections; sodium chloride - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

ARANESP darbepoetin alfa (rch) 30 microgram/0.3mL injection syringe within a pen injector Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 30 microgram/0.3ml injection syringe within a pen injector

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; water for injections; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

ARANESP darbepoetin alfa (rch) 100 microgram/0.5mL injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 100 microgram/0.5ml injection syringe

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: polysorbate 80; monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium chloride; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

ARANESP darbepoetin alfa (rch) 80 microgram/0.4mL injection syringe with automatic needle guard Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 80 microgram/0.4ml injection syringe with automatic needle guard

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; polysorbate 80; sodium chloride; dibasic sodium phosphate; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy